VivaVision, a company incubated and invested by Viva Biotech, recently announced the completion of Series D2 financing round over 100 million RMB. This financing round was jointly completed by V Capital, Shengze Investment, Sunbow Capital, VVB Fund and other institutions. The completion of the new financing round not only represents a significant affirmation of VivaVision's innovative achievements but also indicates positive expectations for its long-term development. The proceedings from this round will be used for the advancement of clinical trials of multiple ophthalmic innovative drugs, preclinical pipeline research and development, and the expansion of technology innovation platforms. The company is actively accelerating commercial cooperation on the mid-to-late-stage pipeline and pursuing forward-looking industrialization strategies.

VivaVision's current pipeline includes three clinical-stage products: VVN001 for treating dry eye syndrome, VVN539, a novel dual-targeting small molecule drug for glaucoma or ocular hypertension, and VVN461 for the treatment of non-infectious ocular inflammation of Uveitis. Notably, VVN001 is the second leading pipeline globally and has completed Phase II clinical studies in both China and US, yielding exciting and positive results.

About VivaVision Biotech

VivaVision is a clinical stage pharmaceutical company focused on best-in-class and first-in-class therapies for ocular diseases. VivaVision's current pipeline includes VVN001 for treating dry eye syndrome, VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious ocular inflammation of Uveitis. VivaVision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases. For more info, visit